Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Satiogen Pharmaceuticals has discovered a mechanism of action that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed drugs. This “Bile Acid Brake” is a metabolic regulatory mechanism which potently suppresses food intake and postprandial glucose when excessive amounts of bile acids arrive in the colon and rectum. There, bile acids are ligands for intraluminal G-prote...
Satiogen Pharmaceuticals has discovered a mechanism of action that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed drugs. This “Bile Acid Brake” is a metabolic regulatory mechanism which potently suppresses food intake and postprandial glucose when excessive amounts of bile acids arrive in the colon and rectum. There, bile acids are ligands for intraluminal G-protein coupled receptors on colorectal L-cells which secrete multiple metabolic hormones that regulate satiety and glucose homeostasis.

List your booth number for exhibitions, ask us